

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

## GUIDANCE OF EFSA

# Guidance on Statistical Reporting<sup>1</sup> European Food Safety Authority<sup>2,3</sup>

European Food Safety Authority (EFSA), Parma, Italy

### ABSTRACT

Statistical analyses are an essential part of risk assessments. Statistical reporting varies considerably amongst the documents that EFSA receives and produces, which can lead to lack of transparency and reproducibility of results. This guidance aims to improve quality, openness and transparency of EFSA's work and information/analyses received by EFSA (including dossiers). It is not intended to provide guidance on which statistical methodology should be applied and how statistical analysis should be performed. A template is proposed, that covers in the broadest possible way, the reporting of relevant aspects of a statistical analysis including: objectives, sources of information (data), study design, data quality, analysis methods, results and interpretation. The guidance and template serve to harmonise and standardise statistical reporting to allow for reproducibility of results and to facilitate independent peer review.

© European Food Safety Authority, 20YY

### KEY WORDS

Statistical reporting, study design, sampling, guidance, statistics

---

<sup>1</sup> On request from EFSA, Question No EFSA-Q-2012-00625, approved on DD Month YYYY.

<sup>2</sup> Correspondence: [amu@efsa.europa.eu](mailto:amu@efsa.europa.eu)

<sup>3</sup> Acknowledgement: EFSA wishes to thank the members of the Working Group on Statistical Reporting: Jean-Louis Bresson, Mikolaj Gralak, Matthias Greiner, Andy Hart, Joe Perry and Hans-Hermann Thulke for the preparatory work on this scientific output and EFSA staff: Davide Arcella, Saghir Bashir, Andreia Carlos and Laura Martino for the support provided to this scientific output.

Suggested citation: European Food Safety Authority, 20YY. Guidance on Statistical Reporting. EFSA Journal 20YY;volume(issue):NNNN, 19 pp., doi:10.2903/j.efsa.20YY.NNNN.

Available online: [www.efsa.europa.eu/efsajournal](http://www.efsa.europa.eu/efsajournal)

19 **SUMMARY**

20 EFSA mandated itself to develop a guidance on statistical reporting to improve the quality, openness  
21 and transparency of EFSA's work and information/analyses received by EFSA. The guidance aims for  
22 harmonisation and standardisation in the reporting of statistical analysis. In view of the nature of the  
23 subject, the task was assigned to the Assessment and Methodological Support Unit (formerly  
24 Scientific Assessment Support Unit).

25 The risk assessment process often requires quantitative evaluation of scientific studies from different  
26 sources (e.g. dossiers, journal publications, technical reports). The reporting of statistical methodology  
27 (including design), analysis and results varies considerably. Lack of relevant information can lead to  
28 delays in the review process whilst additional information is sought from the originating source. If the  
29 statistics were consistently reported in a harmonised and standardised way then this would benefit both  
30 EFSA and its stakeholders. This approach would be more open and transparent.

31 The guidance should best guide EFSA panels, Scientific Committee, working groups, units and  
32 stakeholders on how to report statistical methodology (including design and conduct), analyses and  
33 results (i.e. "explain to the reader what was done") in order to allow independent peer review (by a  
34 statistician) and reproducibility. For EFSA outputs this guidance is valid when the main outcome of  
35 the opinion or report is based on a statistical analysis.

36  
37 The issue of what methodologies should be used for the design, conduct and analysis are outside the  
38 scope of this mandate.

39 The guidance is intended to be general and provide guidelines on the reporting regardless of the type  
40 of analysis that was performed. For this reason some aspects that are listed and discussed might not be  
41 applicable to a specific study design and/or data analysis.

42 To facilitate the practical use of the guidance, a template is proposed, that covers in the broadest  
43 possible way, the reporting of relevant aspects of a statistical analysis including: objectives, sources of  
44 information (data), study design, data quality, analysis methods, results and interpretation. The  
45 guidance and template aim to harmonise and standardise statistical reporting in such a way that  
46 reproducibility of results and independent peer review is feasible.

47 The general and specific objectives of the statistical analysis should be stated with scientific  
48 background explaining the rationale for the analysis. The sources of information (data) used for the  
49 analysis and data quality assurance measures should be reported. These could be pre-existing sources  
50 or data specifically collected. The data sources will be dependent on some underlying study design and  
51 all measures taken to minimise bias and maximise precision should be detailed. This, together with  
52 approached used to address sample selection, sample size, power, blinding (where relevant) and  
53 randomisation (where relevant) should be detailed.

54 Statistical analysis, including data processing (e.g. transformation of data), details of the methodology  
55 (e.g. assumptions, models used) and the software used, have to be documented. Any deviations from  
56 any protocol and/or analysis plan must be justified. The reporting of the results should be consistent  
57 with the objectives of the study. Descriptive statistics should be presented for all data collected for  
58 analysis. The point and interval estimates (e.g. confidence) for all results of the statistical analysis  
59 should be presented. A statistical interpretation of results to support the biological/scientific  
60 interpretation should be given including a discussion about all relevant uncertainties affecting the  
61 statistical analysis and its results.

62 The template also allows for the inclusion of detailed statistical outputs and supplementary study  
63 information (e.g. protocol) to encourage a fully open and transparent approach to statistical reporting.

64	<b>TABLE OF CONTENTS</b>	
65	Abstract .....	1
66	Summary .....	2
67	Table of contents .....	3
68	Background as provided by EFSA .....	5
69	Terms of reference as provided by EFSA .....	5
70	Introduction to Guidance.....	6
71	Applicability of Statistical Reporting Guidance .....	6
72	Other guidance documents on related topics .....	6
73	Guidance and template .....	7
74	1. Title Page.....	8
75	2. Summary.....	8
76	3. Reporting of objectives and scope.....	8
77	3.1. Background.....	8
78	3.2. General objectives.....	8
79	3.3. Specific objectives .....	8
80	4. Reporting sources of information .....	9
81	4.1. Existing sources of data .....	9
82	4.2. Direct data collection .....	10
83	5. Reporting of study design.....	10
84	5.1. Type of Study Design .....	10
85	5.1.1. Randomisation and Blinding .....	10
86	5.2. Sampling .....	11
87	5.2.1. Experimental and sampling units .....	11
88	5.2.2. Sample size .....	11
89	5.2.3. Sample selection strategy .....	11
90	6. Reporting data quality .....	12
91	6.1. Data collection quality assurance.....	12
92	7. Reporting the Methods of Analysis .....	13
93	7.1. Data processing.....	13
94	7.2. Statistical analysis.....	13
95	7.3. Software .....	14
96	8. Deviation from the protocol and/or analysis plan.....	15
97	9. Reporting the Results.....	15
98	9.1. Endpoint/objective/outcome .....	15
99	9.1.1. Descriptive statistics .....	15
100	9.1.2. Results of statistical analysis .....	15
101	9.1.3. Graphical summaries .....	16
102	10. Reporting the interpretation of the results .....	16
103	10.1. Reporting results and their interpretation.....	16
104	10.2. Reporting Uncertainty.....	16
105	11. Detailed Statistical outputs.....	17
106	11.1. Tables.....	17
107	11.2. Graphs.....	17
108	11.3. Listings.....	17
109	12. Supplementary Study information.....	17
110	12.1. Protocol and protocol amendments.....	17
111	12.2. Sample information (data) collection form .....	17
112	12.3. Statistical analysis plan and amendments .....	17
113	12.4. Randomisation list .....	17
114	12.5. Raw data .....	17
115	12.6. Publications based on the study and/or analysis .....	17
116	12.7. Unpublished references.....	17
117	12.8. Quality assurance procedures.....	17

118 References ..... 19

119

## 120 **BACKGROUND AS PROVIDED BY EFSA**

121 EFSA's mission is to support policy makers in their activity by providing and analysing scientific  
122 evidence. There are differences in the requirements for statistical reporting in regulatory and research  
123 setting. In a research setting, the audience is primarily comprised of peers with scientific expertise in  
124 the topic, whereas in a regulatory setting the primary expertise of the audience may be in other areas  
125 of science, or outside science (e.g. in policy, economics, law, etc.). Furthermore, in a research setting  
126 the focus is on advancing knowledge, including the development and testing of hypotheses, whereas in  
127 a regulatory setting the focus is on making decisions between alternative policies or regulatory  
128 options. These differences have implications for statistical reporting. In a research setting, it is  
129 common to report in detail the methods and assumptions of an analysis, and discuss their validity: the  
130 audience may then use their own expertise to interpret critically the implications of the results and any  
131 associated uncertainties. In a regulatory setting, detailed description is also important for transparency  
132 and peer review, but the regulatory audience will often lack the expertise to interpret for themselves  
133 the impact of assumptions and uncertainties on the conclusions. Therefore, in a regulatory setting, it is  
134 essential not only to report assumptions and the degree to which they are valid, but also to evaluate  
135 and express the impact of this on the interpretation of the results. EFSA work includes evaluations of  
136 submissions from external organisations in relation to regulated products and techniques. In this  
137 context, the reports delivered as supporting documents to EFSA frequently lack key information. As a  
138 consequence there is a need to request clarifications, thus increasing the time and the effort needed for  
139 the assessment. The availability of clear and detailed recommendations on the reporting should help to  
140 shorten the process and minimise disputes.

141 The risk assessment process often requires quantitative evaluation of scientific studies from different  
142 sources (e.g. dossiers, journal publications, technical reports). The reporting of statistical methodology  
143 (including design), analysis and results varies considerably. Lack of relevant information can lead to  
144 delays in the review process whilst additional information is sought from the originating source. For  
145 the statistics were consistently reported in a harmonised and standardised way then this would benefit  
146 of both EFSA and its stakeholders, this guidance aims for harmonisation and standardisation through  
147 the provision of guidelines on peer review and reproducibility. It is designed to improve the quality,  
148 openness and transparency of the work of stakeholders reporting to EFSA and of EFSA's own work in  
149 this area. It is aimed at EFSA panels, Scientific Committee, working groups, units and stakeholders.

## 150 **TERMS OF REFERENCE AS PROVIDED BY EFSA**

151 In view of the above, guidelines should be developed to best guide EFSA panels, Scientific  
152 Committee, working groups, units and stakeholders on how to clearly and concisely report statistical  
153 methodology (including design and conduct), analyses and results (i.e. "explain to the reader what was  
154 done"). The issue of what methodologies should be used for the design, conduct and analysis are  
155 outside the scope of this mandate.

156 The Guidance should be practical and applicable to the different relevant food and feed safety fields,  
157 within EFSA's remit including Animal Health and Welfare and Plant Health. In particular, the EFSA  
158 Guidance should include:

- 159 • how to ensure objective and accurate reporting of statistics;
- 160 • how to document and present the design, methodology, analysis and results to allow  
161 independent peer review;
- 162 • a glossary of relevant terms.

163 A draft version of the Guidance should be made available for the Scientific Committee and for public  
164 consultation, to ensure all relevant information is taken into account with respect to the reliability and  
165 consistency of the methods described in the final document.

166 For the development of this EFSA Guidance, the SAS Unit should establish a working group of EFSA  
167 scientific staff and external experts.

## 168 **INTRODUCTION TO GUIDANCE**

169 This guidance is aimed at covering all areas of EFSA’s remit including:

- 170 • food and feed safety, nutrition, animal health and welfare, plant protection and plant health;
- 171 • impact of the food chain on the biodiversity of plant and animal habitats;
- 172 • environmental risk assessments of genetically modified crops, pesticides, feed additives, and  
173 plant pests.

174 The aim is to improve transparency, support reproducibility and lead to a harmonised and standardised  
175 reporting.

176 It is assumed that the statistical work will be the responsibility of an appropriately qualified and  
177 experienced statistician. The issue of what methodologies should be used for the design, conduct and  
178 analysis are outside the scope of this mandate.

### 179 **Applicability of Statistical Reporting Guidance**

180 The objective of this document is to provide guidance on how to report statistical work in order to  
181 allow the evaluation of the quality and validity of any analyses for appropriate use in EFSA’s risk  
182 assessment process, including dossier reviews. A template is also proposed aimed at facilitating the  
183 implementation of the Guidance.

184 Some requirements for statistical reporting are specific to particular situations which will be indicated  
185 in the guidance and hence will not be applicable to other cases.

### 186 **Other guidance documents on related topics**

187 This document aims to provide a concise and practical overview of the general and specific principles  
188 relevant to EFSA’s work, harmonising them where possible and referring to other existing sources  
189 where applicable. There are various initiatives going on in the scientific community aimed at  
190 providing guidance on how to improve the quality of reporting, for example the EQUATOR network<sup>4</sup>  
191 on reporting of health research, and in particular the CONSORT statement (Schulz et al., 2010) and  
192 the SAMPL guidelines (Lang et al., 2013). The International Conference on Harmonisation (ICH)  
193 Guidelines E3 on “Structure and Contents of Clinical Study Reports” was used as a reference to model  
194 the structure of this guidance document (ICH, 1995).

195 Although there are various initiatives and documents aimed at improving the quality of science none  
196 of them address statistical reporting that could be directly applied to the EFSA context. This was the  
197 main motivation to provide such a guidance document.

198 EFSA has published other relevant guidance documents in the areas of transparency in risk assessment  
199 (EFSA, 2009), systematic reviews (EFSA, 2010), probabilistic modelling (EFSA PPR Panel, 2012),  
200 terminology in risk assessment (EFSA, 2012) and expert knowledge elicitation (EFSA, 2014). EFSA  
201 Scientific Committee has published an opinion on statistical significance and biological relevance  
202 (EFSA, 2011). All these opinions and guidance are of relevance for use in conjunction with this  
203 guidance.

204 The need for transparency in all the steps of risk assessment is emphasized in the general conclusions  
205 of EFSA (2009):

---

4 <http://www.equator-network.org>

- 206 • *The scientific outputs must be transparent with regard to the data, methods of analysis and*  
207 *assumptions that are used in the risk assessment process;*
- 208 • *Transparency is needed in all parts of the risk assessment;*
- 209 • *To be transparent, a risk assessment should be understandable and reproducible;*
- 210 • *Where possible, harmonised assessment terminology should be used, preferably based on*  
211 *internationally accepted terminology;*
- 212 • *There may be differences in risk due to variability among individuals, populations, species or*  
213 *ecosystems. It is important to identify and describe the most influential contributors to*  
214 *variability in risk, preferably by statistical analysis of the underlying data;*
- 215 • *Any statistical difference must be interpreted in the light of its biological relevance;*
- 216 • *Although it may be impossible to identify all the uncertainties, each scientific output should*  
217 *describe the types of uncertainties encountered and considered during the different risk*  
218 *assessment steps, and indicate their relative importance and influence on the assessment*  
219 *outcome;*
- 220 • *Expression of uncertainty and variability in risk estimates may be qualitative or quantitative,*  
221 *but should be quantified to the extent that is scientifically achievable.*

## 222 **GUIDANCE AND TEMPLATE**

223 The following sections of this document offer guidance on the specific steps that are needed to achieve  
224 the principles of transparency summarised above in reporting statistical analysis. This document is  
225 presented in a concise form which is intended to serve also as a template for applying the guidance in  
226 practice.

227 When the main outcome of the opinion or report is based on a statistical analysis this guidance should  
228 be followed. In some cases, details of statistical analysis are reported in the main body of an opinion,  
229 report or application. In other cases, detailed reporting is provided in an Annex or other supporting  
230 document. The following guidance applies equally to both cases (except for Sections 1 and 2, see  
231 below). In the first case also compliance with the EFSA template for opinions and other scientific  
232 outputs should be assured. Where the guidance requires more detail than is practical in the main body  
233 of a document, it should be provided in an Annex or supporting materials. However, detailed reporting  
234 is not required where a narrative summary is given of the results of statistical analysis that is already  
235 fully reported elsewhere and this guidance does not apply in such cases.

236 These guidelines and template are for use equally by EFSA panels, Scientific Committee, working  
237 groups, units and stakeholders (e.g. applicants). In practice, for EFSA, this would mean that all  
238 statistical analysis conducted internally, or as part of a grant or procurement should follow the  
239 guidelines and template. Stakeholders submitting statistical analyses to EFSA (e.g. statistical reports  
240 for studies supporting an application) should also follow these guidelines.

241



242 **1. Title Page**

243 Where the statistical analysis is subject of a separate document, the title page should contain the  
244 following information:

- 245 • Statistical Report Title (covering key information, e.g. design);
- 246 • Abstract and keywords;
- 247 • Name of sponsor (and bodies that fund or commission the analysis);
- 248 • Relevant identification number(s) (e.g. protocol, mandate and question numbers);
- 249 • Name and affiliation of person or persons responsible for writing and signing off the report;
- 250 • Date and version of report.

251 Where the statistical analysis is reported as part of a larger document (e.g. a Panel Opinion), the title  
252 page should follow the usual conventions for the type of document in question.

253 **2. Summary**

254 The summary is intended to provide a concise description of the key elements of the objectives,  
255 design, methods and analysis. The key numerical results with quantified uncertainty (e.g. interval  
256 estimates) should also be included. It should also include a brief summary of any important additional  
257 uncertainties that have not been quantified. Where the statistical analysis is part of a larger document  
258 (e.g. a panel opinion, dossiers), it is recommended that if key numerical results are identified, these  
259 should be included as part of the overall summary of the document.

260 **3. Reporting of objectives and scope**

261 **3.1. Background**

262 The scientific background should be presented in order to help the reader understand the rationale for  
263 performing the statistical analysis and what gaps in the current knowledge are intended to be  
264 addressed.

265 **3.2. General objectives**

266 The general objective of the statistical analysis should be described in a narrative form.

267 The regulatory setting might play a role in determining the objectives of the analysis and indicating  
268 constraints and priorities. If this is the case those elements should be mentioned.

269 **3.3. Specific objectives**

270 The specific objectives of the analysis have to be elaborated in both a formal and narrative way. It  
271 should be stated whether they are:

- 272 • to explore and describe the data at hand in order to generate new hypotheses (exploratory  
273 analysis (see ICH (1998) for definition));
- 274 • to estimate a predefined quantity (e.g. estimation of exposure, bench mark doses, prevalence);
- 275 • to confirm predefined hypotheses (confirmatory analysis (see ICH (1998) for definition)).

276 Any hypotheses intended to be tested have to be stated formally, including the endpoints to be  
277 considered, the significance level and the power of the test. For estimation, the confidence interval to



278 be used should be specified and justified. It should be reported whether the existence of a difference or  
279 the evaluation of the equivalence is to be assessed, as well as the size of the difference/range of  
280 equivalence considered biologically relevant (EFSA, 2010).

281 The target population has to be specified in order to allow for the generalisation of the results. If  
282 subgroups of the population have been specifically addressed by the analysis, they should be described  
283 along with the rationale for their choice. Characteristics of the subjects that constitute the population  
284 should be identified (e.g. gender, age, ethnicity, species/category/varieties, geographical location,  
285 temporal frame).

#### 286 **4. Reporting sources of information**

287 This section should describe the data source or sources that were used (e.g. existing data and/or  
288 databases, experimental studies, literature review).

289 The rationale for the use of a specific source generating the data for the statistical analysis should be  
290 reported, including the procedural and/or experimental conditions under which the data were  
291 assembled/collected and that could limit the scope of the analysis.

292 If multiple data sets are used then it should be reported how they were combined. For example, to  
293 estimate prevalence, the number of cases could be extracted from an animal register and total  
294 population size from trade data.

##### 295 **4.1. Existing sources of data**

296 All the information needed to retrieve the data from the original sources should be documented (e.g.,  
297 websites, date of download/receipt).

298 If existing databases were used, the related metadata should also be provided (or referred to in case  
299 published somewhere) including:

- 300 • nature of the data (e.g. administrative data, primary data);
- 301 • institution in charge of data management;
- 302 • methodology used to collect data (e.g. statistical unit, reference population, study design,  
303 sampling strategy, nomenclature, measurement unit);
- 304 • date/period of data collection;
- 305 • confidentiality issues (if applicable).

306 Unpublished data should be included in the report. If not, full description of the data and a justification  
307 of why the data could not be attached should be given (see section 12).

308 Procedural conditions should be reported e.g. inclusion/exclusion criteria as applied to select sub-sets  
309 of the existing data. For example criteria based on:

- 310 • relevance for the specific issue (e.g. exposure assessment of (sub)populations, geographical  
311 regions, materials or test organisms used);
- 312 • specific requirements for the purpose of the analysis (e.g. coverage of endpoints, sensitivity,  
313 specificity, appropriate statistical treatment of data, representativeness of data);
- 314 • study design (e.g. robustness of statistical design, potential bias).

315 **4.2. Direct data collection**

316 If the study included collecting data that was subsequently analysed, the method of data collection  
317 should be documented as part of the planned study design (see section 5).

318 **5. Reporting of study design**

319 This section addresses the key features of the design that should be covered. However, some of the  
320 sub-sections may not be applicable to particular study designs/situations and in those cases the section  
321 should remain with the text “Not applicable”. The rationale for the study design should be documented  
322 and a protocol (or any *a priori* plan) attached (see Section 12.1). In cases where a design element (e.g.  
323 blinding), that should be present for a particular study design, is missing then its omission should be  
324 justified.

325 **5.1. Type of Study Design**

326 The following items should be documented:

- 327 • The type of design of the experiment/study/survey (e.g. factorial, cohort, case-control, cross-  
328 sectional, longitudinal, stratified, clustered);
- 329 • The interventions by treatment level and administration route (if applicable);
- 330 • The expected biologically relevant effect (if applicable);
- 331 • The setting (e.g. location, dates);
- 332 • The eligibility criteria (if applicable);
- 333 • The timescale (e.g. acute vs. chronic exposure) with the duration of treatment and follow-up  
334 (if applicable);
- 335 • Spatial scale and environmental conditions (if applicable);
- 336 • The primary and secondary endpoints along with auxiliary and confounding factors (if  
337 applicable);
- 338 • The persons involved in each phase of the implementation process including providers, data  
339 collectors and outcome adjudicators;
- 340 • Method of data collection (e.g. interview, medical examination, etc.) (if applicable);
- 341 • For cohort studies, the follow-up process should be reported, providing information related to  
342 matching criteria and number of individuals exposed and non-exposed;
- 343 • For case-control studies, the choices of cases and controls should be reported and justified,  
344 and in the case of matching, the criteria and number of controls per case should be presented.
- 345 • Stopping rules (if applicable).

346 The elements to be considered to develop a protocol for a systematic review are listed in the EFSA  
347 Guidance on Systematic review (EFSA, 2010; Section 3.1) and for the reporting of a systematic  
348 review these same elements should be included.

349 **5.1.1. Randomisation and Blinding**

350 In case of randomisation and/or blinding the reporting should cover:

- 351       • the method to generate the random allocation sequence;
- 352       • the type of randomisation;
- 353       • level at which the randomisation was applied (see Section 5.2.1);
- 354       • the mechanism to implement the random allocation sequence;
- 355       • Blocking/clustering and/or stratification (see Section 5.2.3);
- 356       • methods to conceal intervention sequence;
- 357       • the persons involved in each phase of the implementation process including their access to the  
358       randomisation list, with dates.
- 359       • Access to the blinding list (if applicable) should be reported with respect to the date of access,  
360       the accessing person, and reason.

361   **5.2.    Sampling**

362   The sampling strategy should be reported, including the definition of the sampling unit, the sample  
363   size required according to meet the objectives and the sampling design used to get the sample from the  
364   target population.

365   **5.2.1.   Experimental and sampling units**

366   The definition of the experimental unit should be provided. For example, in an experimental setting  
367   with two rats per cage it should be specified whether the treatment(s) were randomised at the level  
368   of the cage or the individual rat.

369   The definition of the sampling unit should be provided. If two-stage sampling is practiced, e.g., in  
370   surveys of farmed animal populations, the sampling units at all levels should be described.

371   It should also be stated which unit, sampling or experimental, was considered for each statistical  
372   analysis.

373   **5.2.2.   Sample size**

374   The rationale of the sample size adopted, together with any calculation on which it was based, should  
375   be reported in terms of:

- 376       • the biologically relevant effect or expected estimate;
- 377       • the precision of measurements;
- 378       • the level of confidence (if applicable);
- 379       • the power of the study (if applicable);
- 380       • the feasibility, time and budget constraints (Eurostat, 2008).

381   Methods and results of sample size/power calculation used should be described.

382   **5.2.3.   Sample selection strategy**

383   A description of the sampling design should be provided as well as the rationale supporting the choice  
384   (e.g. in the survey context: a clustered sample could be adopted instead of a stratified sample for

385 budgetary reason; in the experimental setting: a blocking design may be adopted instead of a  
386 completely randomized design, etc.).

387 If the approach taken in the sample selection is not based on a random selection then a justification  
388 should be provided, especially with respect to representativeness. Relevant differences between the  
389 general population and the selected sample should be reported.

390 It should be mentioned whether any auxiliary information was used in order to improve the efficiency  
391 of the sampling design (e.g. stratification variables) or to reflect the aggregation of sampling units  
392 (clustering). If an informed choice in terms of resource allocation has been made to optimise the  
393 sample size of primary (e.g. herds) and secondary sampling units (e.g. animals per herd), the rationale  
394 and supporting evidence should be described.

395 Any sub-sampling (e.g. where there are five animals per cage and only one is selected for  
396 necropsy/blood sampling) should be documented including if such selection is random.

397 Any known or plausible deviation from independence among the sampling units should be described.  
398 For example, if individual animals come from the same litter or if individuals are repeatedly sampled  
399 over time.

400 Specific sampling designs, such as for example pooled samples, should be described in sufficient  
401 detail to allow a critical review.

## 402 **6. Reporting data quality**

403 This section addresses the reporting of the elements of data collection and pre-processing that could  
404 influence data quality. However, some of the sections may not be applicable to particular study  
405 designs/situations and in those cases the section should remain with the text “Not applicable”. If no  
406 quality control or quality assurance procedures were used then this should be stated with justification.  
407 The details of the procedures used should be provided in Section 12.8.

### 408 **6.1. Data collection quality assurance**

409 All the actions put in place in order to minimise bias and maximise precision at the level of data  
410 collection should be described including:

- 411 • training of data collectors (if applicable);
- 412 • pilot test of the questionnaire (if applicable);
- 413 • methodology used to input data;
- 414 • methodology used to edit data (e.g. macro or micro-editing, list of checks applied to identify  
415 mistakes);
- 416 • methodology used to impute missing data;
- 417 • methodology used to prevent measurement errors.

418 Any pre-processing activities performed on the extracted data that could affect results such as  
419 computation of standard errors on the basis of confidence intervals and/or transformation of  
420 measurement unit (e.g. from mmol to mg) should be documented. For systematic reviews it should be  
421 also stated which criteria were used to assess the methodological quality of individual studies and how  
422 the quality appraisal was used in weighting the evidence.

423 **7. Reporting the Methods of Analysis**

424 When analysing confirmatory studies and estimation, a priori definition of the methods for analysis  
425 may be critical to the interpretation of results. For such analyses, therefore, reporting should describe  
426 and justify the initial pre-defined plan for processing and analysis of data and any additions, deviations  
427 or adjustments made during the course of the analysis.

428 For exploratory studies, it is sufficient to describe the analysis as it was conducted. This should  
429 include a full description of the methods used for the final analysis, i.e., the analysis that generated the  
430 results as presented. If the final analysis was preceded by a series of significantly different analyses, it  
431 is recommended to provide an overview of those and explain the rationale that led to the choice of the  
432 final analysis.

433 **7.1. Data processing**

434 All methods used for processing of data should be reported and justified, where alternative approaches  
435 could be considered. This includes:

- 436 • Transformations (e.g. the use of logarithms and the base of the logarithms should be made  
437 explicit);
- 438 • Processing for the creation of descriptive summaries or graphs (e.g. calculation of averages or  
439 percentages, pooling of different subsets of data, selection of bin intervals for histograms);
- 440 • Treatment of missing or censored data;
- 441 • Identification and handling of outliers;
- 442 • Methods used for selection and/or weighting of data (including, in the case of systematic  
443 reviews, appraisal of the methodological quality of studies);
- 444 • Any other methods used for processing data.

445 **7.2. Statistical analysis**

446 Most analyses involve some form of explicit or implicit statistical modelling. The following should be  
447 included when reporting the methods used:

- 448 1. For estimation, precise specification of the parameter to be estimated and the estimator chosen  
449 to estimate it (e.g. ratio estimator, post-stratified estimator);
- 450 2. For exploratory or confirmatory studies, specification of the hypotheses tested.
- 451 3. Choice and justification for probability levels to be used for interval estimation and hypothesis  
452 testing (if not already specified in the analysis objectives as described in Section 3.3).
- 453 4. Brief description of alternative models considered, rationale for selection of the chosen model,  
454 and justification of its suitability to address the objectives of the analysis.
- 455 5. For Bayesian models, a description and justification of the prior distributions along with the  
456 sources of information and how they have been derived in case of informative priors.
- 457 6. Complete specification and justification of the chosen model, such that it can be reproduced  
458 by others, including:
  - 459 a. list of model parameters, covariates and response variables;

- 460            b. model equations, formulas;
- 461            c. treatments Factors, blocking factors (if applicable);
- 462            d. fixed effects versus random effects (if applicable);
- 463            e. model building procedure (if applicable intermediate model results should be shown);
- 464            f. specification and justification of all assumptions, including those regarding
- 465                distributions and dependencies (including absence of dependency). For generalized
- 466                linear models, the choice of error distributions and link functions.
  
- 467        7. Identification and justification of data selected for use in the model.
- 468        8. Identification and justification of any relevant data that are excluded from the model (e.g.
- 469                outliers).
- 470        9. Treatment of missing or censored data within the model, including imputation, and any
- 471                assumptions implied by this.
- 472        10. Description and justification of methods used for any weighting of data within the model.
- 473        11. Specification of the parameter estimation methodology (e.g. Restricted Maximum Likelihood,
- 474                Bayesian, Markov Chain Monte Carlo, Integrated Nested Laplace Approximation).
- 475        12. Description and justification of any methods used to handle multiplicity in hypothesis testing
- 476                or interval estimation (if applicable).
- 477        13. Description of methods used for producing any model diagnostics.
- 478        14. Description and justification of methods used for testing model assumptions.
- 479        15. For Bayesian models, a sensitivity analysis for describing the impact of alternative priors (if
- 480                applicable) on the posterior distribution.
- 481        16. Description and justification of methods used for additional analysis of the model, e.g.
- 482                subgroup analysis and meta-regression (Liberati et al., 2009).
- 483        17. Description and justification of any other methods used for validating and/or verifying the
- 484                model or assessing its robustness or performance e.g. sensitivity analysis.

485    **7.3.    Software**

486    Where the analysis has been conducted with any software package it should be identified in the report  
 487    (including version and operating system). If additional details are needed to enable reproduction of the  
 488    analysis, these should be provided.

489    Where the analysis has been conducted with a purpose-built computer program, this should be  
 490    described in the report and the program (with sufficient commenting) should be made available in  
 491    electronic form.

492    All programs, log and outputs for the final analysis (i.e. the results and analysis reported) should be  
 493    made available on request for review in electronic format. Tables, graphs and listings should clearly  
 494    state the name of the program that created them with the date and time of run.

495 **8. Deviation from the protocol and/or analysis plan**

496 Deviations and/or non-compliance issues, planned or unplanned, in relation to the a-priori  
497 protocol/statistical plan should be reported and reasons given in this section.

498 **9. Reporting the Results**

499 The analysis report should include its results including descriptive statistics and modelling outputs  
500 (including a quantification of precision). Whenever any transformation is applied to the data (e.g. log,  
501 percent change) then results should be presented for the transformed values along with the results in  
502 the original measurement units.

503 **9.1. Endpoint/objective/outcome**

504 For each endpoint, objective or outcome a subsection should be created within this section with a clear  
505 title following the structure described below.

506 **9.1.1. Descriptive statistics**

507 Descriptive statistics should be presented for all data considered in an analysis, whether used in the  
508 final analysis or not. A combination of tables and graphs should be used to communicate the key  
509 features of the data. Where this results in a large volume of material, tables and graphs in the main  
510 report could be restricted to those variables most critical to the analysis, with others being placed in  
511 annexes or accompanying documents (Section 11).

512 Quantitative summary statistics presented will depend on the type of variable and should at the very  
513 least include the following:

- 514 • Categorical and ordinal variables:
- 515     ○ Percentage(s) presented with both the numerator and the denominator(s).
- 516 • Continuous variables:
- 517     ○ median, lower quartile, upper quartile, minimum and maximum values;
- 518     ○ for data approximately normally distributed, means and standard deviations;
- 519     ○ graphical presentation of the distribution especially where data are not approximately  
520 normally distributed.

521 In case of a systematic review any sources of heterogeneity should be described at least in a narrative  
522 form. If a quantitative heterogeneity analysis is performed, its results should be included in the report.

523 **9.1.2. Results of statistical analysis**

524 The reporting of the main results should be consistent with the objectives of the study as discussed in  
525 Sections 3.2 and 3.3. The point and interval estimates (e.g. confidence) for all results from the  
526 statistical analysis should be presented. Where the analysis provides full distributions for estimators  
527 they should be provided (e.g. Bayesian method, bootstraps).

528 **9.1.2.1. Results of supporting analysis**

529 Supporting analysis should be reported in a consistent manner to the main statistical analysis, making  
530 the intention of the analysis clear, for example;

- 531 • Model diagnostics;



- 532 • Missing data imputation;
- 533 • Testing model assumptions;
- 534 • Model building including intermediate model results (if applicable);
- 535 • Model validation;
- 536 • Assessing robustness or performance (i.e. sensitivity analysis);
- 537 • Additional analysis of the model, e.g. subgroup analysis and meta-regression;
- 538 ○ For confirmatory analysis, whether such analysis was post-hoc.

### 539 9.1.3. Graphical summaries

540 Graphs should be designed carefully to allow objective assessment and the following points should be  
541 taken into consideration:

- 542 • The image should not be distorted (e.g. use appropriate scales for axes);
- 543 • Keep colour coding consistent across graphs;
- 544 • Use high quality graphs with fonts that are readable;
- 545 • Do not use superfluous three-dimensional graphics (e.g. shadows) in bar, line and pie charts.

546 Data used for a graph should be available in Tables or Listing in the body of the report or in Sections  
547 11.1 and 11.3.

## 548 10. Reporting the interpretation of the results

### 549 10.1. Reporting results and their interpretation

550 The reporting should cover all the results of the analysis regardless of whether they were statistically  
551 significant or not. The interpretation of the results should be consistent with the objective and the  
552 design of the analyses (e.g. firm conclusions cannot be drawn based on an exploratory analysis). The  
553 biological relevance should be discussed in parallel with the statistical significance (EFSA, 2011). The  
554 conclusions should reflect the outcomes of the statistical analyses performed.

555 In the case of a narrative summary of different results performed without a meta-analysis, the level of  
556 heterogeneity in the methodological quality of the different sources of evidence, and the weights given  
557 to the outcomes from these sources, should be described.

### 558 10.2. Reporting Uncertainty

559 Each scientific output should describe the types of uncertainties encountered and considered during  
560 the different risk assessment steps, and indicate their relative importance and influence on the  
561 assessment outcome (EFSA, 2009). In the context of a statistical analysis, this should start with the  
562 presentation of the measures of uncertainty generated by the analysis, e.g. interval estimates,  
563 coefficient of variation, etc. In addition, all other elements introducing uncertainty should be  
564 described, including:

- 565 • Assumptions made in the analysis (e.g. model choice, distributional assumption), and the  
566 extent to which they are valid;

- 567 • Direction and magnitude of potential biases, including deviations from the design;
- 568 • Degree of generalizability and applicability to the target population (also referred to as  
569 external validity);
- 570 • Level of heterogeneity in outcomes;
- 571 • Any other choices (e.g., prior distributions).

## 572 **11. Detailed Statistical outputs**

573 The essential/important results should be presented in summary form in the body of the report.  
574 Detailed and supporting results should be presented in this section and cross referenced in the text.

### 575 **11.1. Tables**

576 This section should present tabulated summary results. The tabulations can include both  
577 summary/descriptive statistics and outputs from statistical modelling.

### 578 **11.2. Graphs**

579 This section should present graphical summary results for which there should also be a table presented  
580 in the Section 11.1.

### 581 **11.3. Listings**

582 This section should present listings of individual data that is referenced in the report. Also see Section  
583 12.5) for details about providing the electronic version of the data.

## 584 **12. Supplementary Study information**

585 Key study information and documents, with signature and dates, should be attached to this section as  
586 described in by the sections below. If documents listed are not available then it should be stated why.

### 587 **12.1. Protocol and protocol amendments**

### 588 **12.2. Sample information (data) collection form**

### 589 **12.3. Statistical analysis plan and amendments**

### 590 **12.4. Randomisation list**

### 591 **12.5. Raw data**

592 The raw data should be provided in electronic format or a link to a database in case they are publicly  
593 available in order to allow the replication of the analysis. Raw data should be accompanied by a data  
594 dictionary containing the description of the variables and the metadata needed to properly analyse  
595 them. The details and structure of the electronics files should be presented in this section.

### 596 **12.6. Publications based on the study and/or analysis**

### 597 **12.7. Unpublished references**

### 598 **12.8. Quality assurance procedures**

599 Measures taken to ensure the quality of the data, analysis and reporting should be reported in this  
600 section. These can include data/information versioning, QC of the programmes used for analysis and  
601 processing, versioning of the outputs and the QC measures to ensure any results presented in the body

602 of the report. All measures taken to minimise bias should also be presented here. If QC measures are  
603 not taken then this situation should be justified.

604

605 **REFERENCES**

- 606 EFSA (European Food Safety Authority), 2009. Guidance of the Scientific Committee on  
607 Transparency in the Scientific Aspects of Risk Assessments carried out by EFSA. Part 2: General  
608 Principles. The EFSA Journal 2009, 1051,1-22.
- 609 EFSA (European Food Safety Authority), 2010. Application of systematic review methodology to  
610 food and feed safety assessments to support decision making. EFSA Journal 2010;8(6):1637. 90  
611 pp.. doi:10.2903/j.efsa.2010.1637.
- 612 EFSA (European Food Safety Authority), 2014. [ADD Citation to Expert Knowledge Elicitation](#)  
613 [Guidance– when published.](#)
- 614 EFSA Panel on Plant Protection Products and their Residues (PPR), 2012. Guidance on the Use of  
615 Probabilistic Methodology for Modelling Dietary Exposure to Pesticide Residues. EFSA Journal  
616 2012;10(10):2839, 95 pp. doi:10.2903/j.efsa.2012.2839.
- 617 EFSA Scientific Committee (SC), 2011. Statistical Significance and Biological Relevance. EFSA  
618 Journal 2011;9(9):2372, 17 pp. doi:10.2903/j.efsa.2011.2372.
- 619 EFSA Scientific Committee (SC) 2012. Scientific Opinion on Risk Assessment Terminology. EFSA  
620 Journal 2012;10(5):2664, 43 pp. doi:10.2903/j.efsa.2012.2664.
- 621 Eurostat, 2007. Handbook on Data Quality Assessment Methods and Tools. Available online:  
622 [http://epp.eurostat.ec.europa.eu/portal/page/portal/quality/documents/HANDBOOK%20ON%20](http://epp.eurostat.ec.europa.eu/portal/page/portal/quality/documents/HANDBOOK%20ON%20DATA%20QUALITY%20ASSESSMENT%20METHODS%20AND%20TOOLS%20%20I.pdf)  
623 [ATA%20QUALITY%20ASSESSMENT%20METHODS%20AND%20TOOLS%20%20I.pdf](http://epp.eurostat.ec.europa.eu/portal/page/portal/quality/documents/HANDBOOK%20ON%20DATA%20QUALITY%20ASSESSMENT%20METHODS%20AND%20TOOLS%20%20I.pdf)
- 624 Eurostat, 2008. Survey sampling reference guidelines. Introduction to sample design and estimation  
625 techniques. Methodologies and Working papers. Luxembourg: Office for Official Publications of  
626 the European Communities.
- 627 Eurostat, 2009. ESS Standards for Quality Reports. Methodologies and Working papers. Luxembourg:  
628 Office for Official Publications of the European Communities.
- 629 Eurostat, 2009. ESS Handbook for Quality Reports. Methodologies and Working papers.  
630 Luxembourg: office for official publications of the European Communities.
- 631 Lang T A and Altman D G, 2013. Basic statistical reporting for articles published in biomedical  
632 journals: the SAMPL Guidelines. In: Smart P, Maisonneuve H, Polderman A (eds). Science  
633 Editors' Handbook, European Association of Science Editors.
- 634 Liberati et al 2009. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of  
635 Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PloS Medicine,  
636 volume 6, issue 7, e1000100
- 637 ICH (International Conference on Harmonisation of Technical Requirements for Registration of  
638 Pharmaceuticals for Human Use), 1995. Structure and Contents of Clinical Study Reports, E3. ICH  
639 Harmonised Tripartite Guideline. Available online:  
640 [http://www.ich.org/fileadmin/Public\\_Web\\_Site/ICH\\_Products/Guidelines/Efficacy/E3/E3\\_Guideli](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E3/E3_Guideline.pdf)  
641 [ne.pdf](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E3/E3_Guideline.pdf)
- 642 ICH (International Conference on Harmonisation of Technical Requirements for Registration of  
643 Pharmaceuticals for Human Use), 1998. Statistical Principles for Clinical Trials, E9. ICH  
644 Harmonised Tripartite Guideline. Available online:  
645 [http://www.ich.org/fileadmin/Public\\_Web\\_Site/ICH\\_Products/Guidelines/Efficacy/E9/Step4/E9\\_G](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf)  
646 [uideline.pdf](http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf)
- 647 Schulz KF, Altman DG and Moher D, 2010. CONSORT 2010 Statement: Updated Guidelines for  
648 Reporting Parallel Group Randomized Trials. Ann Intern Med 2010;152:726-732
- 649 SDMX (Statistical Data and Metadata eXchange), 2009. SDMX Content-oriented Guidelines.  
650 Available online: [http://sdmx.org/wp-content/uploads/2009/01/00\\_sdmx\\_content-](http://sdmx.org/wp-content/uploads/2009/01/00_sdmx_content-oriented_guidelines_2009.pdf)  
651 [oriented\\_guidelines\\_2009.pdf](http://sdmx.org/wp-content/uploads/2009/01/00_sdmx_content-oriented_guidelines_2009.pdf)